Status:

RECRUITING

Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Lead Sponsor:

Peking University

Conditions:

Breast Cancer Female

Eligibility:

FEMALE

18-70 years

Phase:

NA

Brief Summary

Neoadjuvant chemotherapy (NACT) is standard treatment for many triple-negative (TNBC) and HER2-positive breast cancer. Study showed about half of the biopsy-proven axillary disease will be eradicated ...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Core biopsy confirmed unicentric primary invasive triple-negative or HER2-positive breast cancer. Multifocal or multicentric tumors allowed only if breast-conserving surgery is deemed feasible.
  • At least 18 years of age
  • Initial tumor stage cT1c-T3N0M0 prior to NACT. cN0 stage established by clinical examination and ultrasonography
  • In cases with suspicious lymph node, a negative core biopsy or fine needle aspiration (FNA) biopsy of the sonographically suspected lymph node is required
  • Standard NACT with evident radiologic response
  • Planned breast-conserving surgery with postoperative external whole-breast irradiation

Exclusion

  • History of previous malignancy
  • Histologically proven N1 patients, patients with distant metastasis (M1)
  • Pregnant or lactating patients
  • Inflammatory breast cancer
  • Radiologically non-responsive after NACT
  • Mastectomy planned after NACT
  • planned intraoperative radiotherapy (e.g. Intrabeam) or postoperative partial breast irradiation (e.g. multicatheter technique) alone; both procedures are allowed as boost techniques
  • Written informed consent not obtained

Key Trial Info

Start Date :

July 3 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2028

Estimated Enrollment :

136 Patients enrolled

Trial Details

Trial ID

NCT05314114

Start Date

July 3 2020

End Date

September 1 2028

Last Update

April 18 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University Cancer Hospital

Beijing, Beijing Municipality, China, 100142